Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey S. Flier Sells 11,136 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) Director Jeffrey S. Flier sold 11,136 shares of the company's stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $40.02, for a total transaction of $445,662.72. Following the sale, the director directly owned 24,070 shares of the company's stock, valued at approximately $963,281.40. This represents a 31.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Scholar Rock Stock Down 2.8%

Scholar Rock stock traded down $1.14 during mid-day trading on Tuesday, reaching $39.98. The company's stock had a trading volume of 1,615,723 shares, compared to its average volume of 1,325,355. The business has a 50 day moving average price of $33.76 and a 200-day moving average price of $35.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.25 and a current ratio of 10.25. Scholar Rock Holding Corporation has a twelve month low of $6.76 and a twelve month high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the business posted ($0.59) earnings per share. As a group, analysts expect that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Institutional Trading of Scholar Rock

A number of large investors have recently added to or reduced their stakes in SRRK. CWM LLC lifted its stake in Scholar Rock by 152.8% in the 1st quarter. CWM LLC now owns 996 shares of the company's stock worth $32,000 after acquiring an additional 602 shares in the last quarter. Federated Hermes Inc. purchased a new stake in shares of Scholar Rock in the first quarter worth approximately $71,000. GF Fund Management CO. LTD. boosted its holdings in shares of Scholar Rock by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company's stock worth $77,000 after purchasing an additional 430 shares during the period. Strs Ohio acquired a new stake in shares of Scholar Rock during the first quarter worth approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Scholar Rock by 15.8% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,668 shares of the company's stock valued at $130,000 after buying an additional 500 shares during the period. 91.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SRRK has been the topic of a number of research reports. Lifesci Capital upgraded Scholar Rock to a "strong-buy" rating in a research note on Tuesday, June 3rd. Wedbush reiterated an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a research note on Wednesday, June 18th. Finally, Cantor Fitzgerald assumed coverage on shares of Scholar Rock in a report on Thursday, July 17th. They set an "overweight" rating on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $42.67.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.